OBJECTIVES: To describe the economic results of clinical follow-up and pharmacotherapeutic management of oncology patients.

METHODS: Descriptive cross-sectional study in patients diagnosed with cancer undergoing treatment with oral chemotherapy, evaluated by a team of physicians and pharmacists during 2023. Through continuous pharmacotherapeutic follow-up, medication errors and problems in pharmacological adherence were detected and intervened to guarantee the pertinence, adherence, safety, and effectiveness of the treatments, and the rational use of health resources. A univariate analysis was performed using the statistical package R Core Team Version 4.2 (2022).

RESULTS: 9709 patients were evaluated, and 262 cases were detected to intervene in 239 patients (2.5%), with a mean age of 59 years (SD=17), 66% women. A total of 48.5% of the cases corresponded to therapeutic non-adherence and accumulation of medicines at home, 38.6% prescription errors, 11.8% pharmacological duplications, and 1.2% chronification of unnecessary treatment. The drugs associated were mainly letrozole 9.5%, anastrozole 8.8%, capecitabine 8%, abiraterone 6.1%, temozolamide 4.6% and lenalidomide 4.6%. These pharmaceutical interventions represented savings equivalent to COP 196,8736,803 (501,125.42 USD).

CONCLUSIONS: Clinical follow-up and pharmacotherapeutic management in oncology patients allow for obtaining satisfactory clinical results and a significant economic impact on the health system.